Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide | Collector

All CURRENT NEWS SCIENCE FINANCE BUSINESS SPORTS BOOKS CINEMA MAGAZİNE TRAVEL AND FOOD TECNOLOGY AUTOMOBİLE

The Laotian Times

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. (“Sciwind Biosciences”), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from a head-to-head study (SLIMMER-UP-SWITCH) evaluating ecnoglutide versus semaglutide was presented as a Late-Breaking abstract at the 86th Scientific Sessions of the […]

Go to News Site